Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting new 52-week lows after the drug-maker withdrew its Investigational New Drug application for its antiviral nucleoside treatment for hepatitis C, BCX5191. The FDA has raised concerns related to the drug's preclinical toxicity profile at levels necessary for it to be effective.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Jan 14, 2015)
at Benzinga.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Dec 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs